Assembly Biosciences Company Profile (NASDAQ:ASMB)

About Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences logoAssembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:ASMB
  • CUSIP: 92282210
  • Web: www.assemblybio.com
Capitalization:
  • Market Cap: $557.91 million
  • Outstanding Shares: 17,364,000
Average Prices:
  • 50 Day Moving Avg: $26.13
  • 200 Day Moving Avg: $24.08
  • 52 Week Range: $6.74 - $32.73
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.04 million
  • Price / Sales: 183.52
  • Book Value: $3.26 per share
  • Price / Book: 9.86
Profitability:
  • EBIDTA: ($50,920,000.00)
  • Return on Equity: -68.83%
  • Return on Assets: -43.63%
Debt:
  • Current Ratio: 6.48%
  • Quick Ratio: 6.48%
Misc:
  • Average Volume: 106,611 shs.
  • Beta: 0.76
  • Short Ratio: 6.37
 

Frequently Asked Questions for Assembly Biosciences (NASDAQ:ASMB)

What is Assembly Biosciences' stock symbol?

Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) released its quarterly earnings data on Monday, November, 17th. The company reported ($1.33) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.84. View Assembly Biosciences' Earnings History.

Where is Assembly Biosciences' stock going? Where will Assembly Biosciences' stock price be in 2017?

1 analysts have issued twelve-month price objectives for Assembly Biosciences' stock. Their forecasts range from $35.00 to $35.00. On average, they anticipate Assembly Biosciences' stock price to reach $35.00 in the next year. View Analyst Ratings for Assembly Biosciences.

Who are some of Assembly Biosciences' key competitors?

Who are Assembly Biosciences' key executives?

Assembly Biosciences' management team includes the folowing people:

  • Derek A. Small, President, Chief Executive Officer, Director
  • David J. Barrett CPA,, Chief Financial Officer, Chief Operating Officer
  • Uri Lopatin M.D., Vice President - Research & Development, Chief Medical Officer
  • William R. Ringo, Independent Non-Executive Chairman of the Board
  • Alan James Lewis Ph.D., Director
  • Anthony E. Altig, Independent Director
  • Mark Auerbach CPA,, Independent Director
  • Richard DiMarchi, Independent Director

Who owns Assembly Biosciences stock?

Assembly Biosciences' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include EcoR1 Capital LLC (16.95%), Jennison Associates LLC (11.26%), Vanguard Group Inc. (3.52%), State Street Corp (1.18%), Northern Trust Corp (1.13%) and JPMorgan Chase & Co. (0.96%). View Institutional Ownership Trends for Assembly Biosciences.

Who sold Assembly Biosciences stock? Who is selling Assembly Biosciences stock?

Assembly Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Goldman Sachs Group Inc., EAM Investors LLC, National Asset Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Assembly Biosciences.

Who bought Assembly Biosciences stock? Who is buying Assembly Biosciences stock?

Assembly Biosciences' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, JPMorgan Chase & Co., Northern Trust Corp, AXA, Vanguard Group Inc., Lyon Street Capital LLC, OxFORD Asset Management LLP and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Assembly Biosciences.

How do I buy Assembly Biosciences stock?

Shares of Assembly Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Assembly Biosciences' stock price today?

One share of Assembly Biosciences stock can currently be purchased for approximately $32.13.


MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Assembly Biosciences (NASDAQ:ASMB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (8.93% upside)

Analysts' Ratings History for Assembly Biosciences (NASDAQ:ASMB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Chardan CapitalReiterated RatingBuyMediumView Rating Details
8/19/2016William BlairInitiated CoverageMarket Perform -> OutperformN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Assembly Biosciences (NASDAQ:ASMB)
Earnings by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Earnings History by Quarter for Assembly Biosciences (NASDAQ ASMB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/17/2014Q3 2014($0.49)($1.33)ViewN/AView Earnings Details
4/2/2014($0.28)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Assembly Biosciences (NASDAQ:ASMB)
2017 EPS Consensus Estimate: ($2.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.03)($0.03)($0.03)
Q2 20171($0.79)($0.79)($0.79)
Q3 20171($0.88)($0.88)($0.88)
Q4 20171($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Assembly Biosciences (NASDAQ:ASMB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Assembly Biosciences (NASDAQ:ASMB)
Insider Ownership Percentage: 19.60%
Institutional Ownership Percentage: 72.27%
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Insider Trades by Quarter for Assembly Biosciences (NASDAQ:ASMB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/11/2016Derek A. SmallCEOBuy10,000$5.53$55,300.00View SEC Filing  
5/27/2014Russell H EllisonCEOBuy13,000$0.92$11,960.00View SEC Filing  
5/23/2014David Jonathan BarrettCFOBuy6,980$0.86$6,002.80View SEC Filing  
5/23/2014Russell H EllisonCEOBuy20,000$0.91$18,200.00View SEC Filing  
5/21/2014Russell EllisonCEOBuy10,000$0.87$8,700.00View SEC Filing  
5/20/2014David Jonathan BarrettCFOBuy40,000$0.88$35,200.00View SEC Filing  
2/5/2013Russell H EllisonCEOBuy15,000$2.55$38,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Assembly Biosciences (NASDAQ:ASMB)
Latest Headlines for Assembly Biosciences (NASDAQ:ASMB)
Source:
DateHeadline
americanbankingnews.com logoCritical Contrast: Assembly Biosciences (ASMB) vs. Its Rivals
www.americanbankingnews.com - September 20 at 8:08 AM
americanbankingnews.com logoAssembly Biosciences, Inc. (ASMB) Earns "Buy" Rating from Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM
americanbankingnews.com logoContrasting Assembly Biosciences (ASMB) and Its Competitors
www.americanbankingnews.com - September 17 at 10:16 AM
americanbankingnews.com logoDARA Biosciences (DARA) & Assembly Biosciences (ASMB) Head to Head Review
www.americanbankingnews.com - September 16 at 12:24 PM
americanbankingnews.com logoZacks: Assembly Biosciences, Inc. (ASMB) Given $25.50 Average Target Price by Analysts
www.americanbankingnews.com - September 8 at 4:26 AM
americanbankingnews.com logoContrasting Assembly Biosciences (ASMB) and Aimmune Therapeutics (AIMT)
www.americanbankingnews.com - September 4 at 4:28 AM
americanbankingnews.com logoAssembly Biosciences, Inc. (ASMB) Upgraded to Strong-Buy at BidaskClub
www.americanbankingnews.com - August 27 at 11:02 PM
americanbankingnews.com logoContrasting Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 21 at 10:26 AM
americanbankingnews.com logoAssembly Biosciences, Inc. (ASMB) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - August 19 at 1:32 PM
finance.yahoo.com logoAssembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : August 15, 2017
finance.yahoo.com - August 15 at 10:08 PM
americanbankingnews.com logoAssembly Biosciences, Inc. (NASDAQ:ASMB) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 14 at 4:54 PM
americanbankingnews.com logoAssembly Biosciences, Inc. (NASDAQ:ASMB) Forecasted to Earn Q3 2017 Earnings of ($0.88) Per Share
www.americanbankingnews.com - August 14 at 3:36 AM
americanbankingnews.com logoAssembly Biosciences, Inc. (NASDAQ:ASMB) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - August 13 at 2:06 PM
americanbankingnews.com logoAnalyzing Rockwell Medical (RMTI) and Assembly Biosciences (NASDAQ:ASMB)
www.americanbankingnews.com - August 9 at 10:26 AM
americanbankingnews.com logoReviewing Assembly Biosciences (ASMB) & Supernus Pharmaceuticals (SUPN)
www.americanbankingnews.com - August 6 at 8:22 PM
finance.yahoo.com logoAssembly Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : ASMB-US : August 2, 2017
finance.yahoo.com - August 2 at 4:54 PM
americanbankingnews.com logo Assembly Biosciences, Inc. (ASMB) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - August 2 at 7:18 AM
finance.yahoo.com logoAssembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - July 28 at 5:19 PM
americanbankingnews.com logoHead to Head Contrast: TherapeuticsMD (TXMD) vs. Assembly Biosciences (ASMB)
www.americanbankingnews.com - July 19 at 8:25 AM
americanbankingnews.com logoZacks: Analysts Set $25.50 Price Target for Assembly Biosciences, Inc. (NASDAQ:ASMB)
www.americanbankingnews.com - July 18 at 12:48 AM
americanbankingnews.com logo Assembly Biosciences, Inc. (ASMB) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - June 30 at 10:10 AM
americanbankingnews.com logoCritical Analysis: Macrocure (MCUR) versus Assembly Biosciences (ASMB)
www.americanbankingnews.com - June 29 at 12:42 AM
americanbankingnews.com logoAnalyzing Assembly Biosciences (ASMB) and Advanced Accelerator Applications (AAAP)
www.americanbankingnews.com - June 27 at 10:22 PM
finance.yahoo.com logoETFs with exposure to Assembly Biosciences, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 5:20 PM
finance.yahoo.com logoAssembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : June 13, 2017
finance.yahoo.com - June 13 at 1:22 PM
americanbankingnews.com logoZacks: Assembly Biosciences Inc (ASMB) Given $25.50 Consensus Price Target by Analysts
www.americanbankingnews.com - June 9 at 11:00 AM
seekingalpha.com logoAssembly Biosciences (ASMB) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 4:23 PM
americanbankingnews.com logoHead to Head Contrast: Assembly Biosciences (ASMB) and Bristol-Myers Squibb (BMY)
www.americanbankingnews.com - June 8 at 10:52 AM
americanbankingnews.com logoAssembly Biosciences Inc (ASMB) Now Covered by Chardan Capital
www.americanbankingnews.com - May 30 at 7:32 AM
americanbankingnews.com logo Assembly Biosciences Inc (ASMB) Given $16.00 Consensus Price Target by Analysts
www.americanbankingnews.com - May 24 at 8:36 PM
finance.yahoo.com logoAssembly Biosciences, Inc. – Value Analysis (NASDAQ:ASMB) : May 11, 2017
finance.yahoo.com - May 11 at 9:09 PM
americanbankingnews.com logoBrokers Issue Forecasts for Assembly Biosciences Inc's Q2 2017 Earnings (ASMB)
www.americanbankingnews.com - May 11 at 9:16 AM
finance.yahoo.com logoAssembly Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : ASMB-US : May 9, 2017
finance.yahoo.com - May 9 at 9:08 AM
americanbankingnews.com logoBrokerages Expect Assembly Biosciences Inc (ASMB) to Announce ($0.03) Earnings Per Share
www.americanbankingnews.com - May 9 at 12:40 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Receives Daily Media Impact Rating of 0.20
www.americanbankingnews.com - April 27 at 9:28 AM
americanbankingnews.com logoAnalysts Anticipate Assembly Biosciences Inc (ASMB) to Post ($0.03) Earnings Per Share
www.americanbankingnews.com - April 22 at 12:47 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Receives Daily News Impact Rating of 0.44
www.americanbankingnews.com - April 20 at 8:29 AM
americanbankingnews.com logoAssembly Biosciences (ASMB) Earns Daily Coverage Optimism Score of -0.10
www.americanbankingnews.com - April 14 at 1:08 PM
americanbankingnews.com logoAssembly Biosciences Inc (ASMB) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 13 at 12:14 AM
americanbankingnews.com logoZacks: Assembly Biosciences Inc (ASMB) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:22 PM
americanbankingnews.com logoZacks: Assembly Biosciences Inc (ASMB) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - March 20 at 12:22 PM
finance.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Financials
finance.yahoo.com - March 8 at 4:21 PM
finance.yahoo.com logoAssembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to Allergan
finance.yahoo.com - February 21 at 9:10 AM
streetinsider.com logoAssembly Biosciences (ASMB) Completes Dose Ranging Portion of Phase 1a/1b Trial of ABI-H0731
www.streetinsider.com - February 17 at 6:29 PM
finance.yahoo.com logoAssembly Biosciences Announces Successful Completion of ABI-H0731 Phase 1a Trial and Upcoming Conference Presentations
finance.yahoo.com - February 16 at 8:34 AM
finance.yahoo.com logoAssembly Biosciences (ASMB) Looks Good: Stock Up 13.9%
finance.yahoo.com - January 18 at 4:18 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - January 10 at 8:43 PM
us.rd.yahoo.com logo8:11 am Assembly Biosciences enters into research, development, collaboration and license agreement with Allergan (AGN); Allergan to make upfront payment of $50 mln
us.rd.yahoo.com - January 10 at 3:42 PM
biz.yahoo.com logoASSEMBLY BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure,
biz.yahoo.com - January 10 at 3:42 PM
streetinsider.com logoAllergan (AGN) Enters Licensing Agreement with Assembly Biosciences (ASMB) to Obtain Worldwide Rights to GI Programs
www.streetinsider.com - January 9 at 4:29 PM

Social

Chart

Assembly Biosciences (ASMB) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff